DHEA can downregulate the expression of Src kinase and STAT3 in PASMCs from PAH patients, inhibit their downstream targets Pim1 and NFATc2 expression/activation, restore BMPR2 and miR-204, thereby alleviating adverse reactions such as pulmonary vascular narrowing and increased pulmonary vascular resistance [199]. The gene discussed is BMPR2; the disease is pulmonary arterial hypertension.